APA (7th ed.) Citation

吴迎朝, 陈柳汕, 梁裕琪, 陈洁婷, 黄俊峰, 左谦, & 陈前军. (2025). 基于类器官构建泛TKI提高ET+CDK4/6抑制剂 治疗HR+ /HER2-low乳腺癌疗效的筛选工具. Journal of Practical Medicine / Shiyong Yixue Zazhi, 41(18), 2786. https://doi.org/10.3969/j.issn.1006-5725.2025.18.002

Chicago Style (17th ed.) Citation

吴迎朝, 陈柳汕, 梁裕琪, 陈洁婷, 黄俊峰, 左谦, and 陈前军. "基于类器官构建泛TKI提高ET+CDK4/6抑制剂 治疗HR+ /HER2-low乳腺癌疗效的筛选工具." Journal of Practical Medicine / Shiyong Yixue Zazhi 41, no. 18 (2025): 2786. https://doi.org/10.3969/j.issn.1006-5725.2025.18.002.

MLA (9th ed.) Citation

吴迎朝, et al. "基于类器官构建泛TKI提高ET+CDK4/6抑制剂 治疗HR+ /HER2-low乳腺癌疗效的筛选工具." Journal of Practical Medicine / Shiyong Yixue Zazhi, vol. 41, no. 18, 2025, p. 2786, https://doi.org/10.3969/j.issn.1006-5725.2025.18.002.